HUMAN-HUMAN HYBRIDOMAS FOR CERVICAL CARCINOMA

The antibodies for distinguishing cervical carcinoma cells from normal cells may be obtd. from human hybridomas CLNH5 or 11. The antibodies or their fragments may be labelled, e.g. with a radionucleotide or toxin. The human hybridoma is obtd. by fusion of B-lymphocytes (from human lymphnodes, lymphg...

Full description

Saved in:
Bibliographic Details
Main Authors HAGIWARA HIDEAKI, HANDLEY HAROLD H, GLASSY MARK C
Format Patent
LanguageEnglish
Korean
Published 22.08.1988
Edition4
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
TESTING
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The antibodies for distinguishing cervical carcinoma cells from normal cells may be obtd. from human hybridomas CLNH5 or 11. The antibodies or their fragments may be labelled, e.g. with a radionucleotide or toxin. The human hybridoma is obtd. by fusion of B-lymphocytes (from human lymphnodes, lymphglands, bone marrow, spleen or blood, associated with a neoplasm) with a human fusion parther. The hybridomas are cloned, and the resulting clones are screened for prodn. of monoclonal anti-bodies specific for the tumour cells. The specific clones are then grown to produce the antibodies.
Bibliography:Application Number: KR19830002232